Clinical trials
Neuroendocrine Cancer clinical trials
Below are recruiting neuroendocrine cancer clinical trials, each written for real people, not researchers. We’re tracking 123 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06055439RecruitingPhase 1/Phase 2
CAR T cell therapy for GI cancers
This trial tests a new type of immunotherapy called CAR T cells that target a protein (CDH17) found on certain stomach, colon, and rectal cancers. It's designed for people whose cancer has spread and has been treated before.
Atlanta, GeorgiaAges 18–85 - NCT02688894Recruiting
Molecular testing for relapsed small cell lung cancer
This study uses tumor tissue to look for molecular (biologic) changes after your small cell lung cancer comes back. It may help doctors choose the most appropriate next treatment based on what the cancer’s biology shows.
IncheonAges 20 years+ - NCT05746182Recruiting
Genetic testing program for pancreatic neuroendocrine tumors
This study offers genetic (inherited) testing for people with pancreatic neuroendocrine neoplasms. The goal is to see who may have a genetic predisposition, which can help guide medical care and family risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06062745RecruitingPhase 1
PET scan study for prostate cancer with low PSMA or neuroendocrine features
This study tests a special PET scan (fluciclovine) to see if it can better detect prostate cancer that has low PSMA levels or has changed to a neuroendocrine type. It may help find tumors that standard PSMA scans miss.
Boston, MassachusettsAges 18 years+ - NCT07458906Recruiting
DLL3-targeted PET/CT scan for neuroendocrine cancer
This trial uses a special PET/CT scan that targets a substance called DLL3, found on some cancer cells, to see if doctors can better detect or monitor neuroendocrine carcinoma. It may help you and your doctor get clearer information about your cancer.
Xiamen, FujianAges 18–80 - NCT04166006RecruitingPhase 2
Vaccine made from your tumor cells after surgery for rare cancers
This trial tests a personalized vaccine made from your own tumor material, aiming to lower the chance cancer returns after surgery. It is for people whose rare cancers have been removed completely and who have no standard treatment available after surgery.
Meldola, FCAges 18 years+ - NCT06540937RecruitingPhase 2
Leflunomide for MEN-1 related neuroendocrine tumors
This trial tests if leflunomide, a medication usually used for arthritis, can shrink or slow the growth of neuroendocrine tumors in people with MEN-1 gene mutations. It is for patients whose tumors have worsened after standard treatment.
BeijingAges 18–75 - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT06440057RecruitingPhase 1/Phase 2
Study of ZG006 for advanced lung and neuroendocrine cancers
This trial is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma. The study has two parts: first finding the right dose, then testing it in more people with neuroendocrine carcinoma.
Beijing, Beijing MunicipalityAges 18–75 - NCT05443087Recruiting
Checking blood levels of targeted drugs for digestive cancers
This trial monitors how your prescribed targeted cancer medicine moves through your body by doing extra blood tests. The goal is to understand the drug’s levels and dosing in people with advanced digestive cancers, so treatment can be better managed.
AmiensAges 18 years+ - NCT05053854RecruitingPhase 1
Testing a PARP drug plus targeted radiation for bowel or pancreas tumors
This Phase 1 study tests how safe and effective it is to combine a PARP inhibitor (a targeted cancer medicine) with PRRT, a treatment that delivers radiation directly to certain tumor cells. It is for people with grade 2 neuroendocrine tumors from the pancreas or intestines, especially when scans suggest the tumor will take up the targeted radiation.
Melbourne, VictoriaAges 18 years+ - NCT06276309Recruiting
Protein study of cervical neuroendocrine tumors
This study looks at the proteins in cervical neuroendocrine tumors to understand how they behave and how they affect long-term outcomes. It aims to find new markers that could help predict prognosis and guide treatment.
Fuzhou, FujianAges Any age - NCT04429087RecruitingPhase 1
Test of Obrixtamig for DLL3-positive small cell lung tumors
This Phase 1 study tests different doses of obrixtamig in people with small cell lung cancer and other similar neuroendocrine tumors that test positive for a marker called DLL3. It may help doctors understand safety and the best dose, and possibly improve treatment options when standard therapy didn’t work.
Atlanta, GeorgiaAges 18 years+ - NCT05196087Recruiting
AI system to monitor cancer treatment progress
This trial tests a non-invasive, AI-based monitoring program for people with solid tumors. It aims to help track how you’re doing during or after curative-intent treatment, using information collected without extra procedures.
Toronto, OntarioAges 18 years+ - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT00923026Enrolling by invitation
Follow-up for adults previously treated in NCI surgery studies
This study asks people age 18+ who were previously treated on certain NCI Surgery Branch (NCI-SB) studies to come back for follow-up. It helps researchers understand how patients do over time after those earlier treatments, including some gene therapy studies.
Bethesda, MarylandAges 18 years+ - NCT06344507Recruiting
Registry of Pancreas and Bile Duct Endoscopy Procedures
This study collects pictures and information from people who have a routine endoscopic ultrasound to look at the pancreas and bile ducts. It aims to learn more about these conditions and improve future care.
MilanAges 18 years+ - NCT07121998Recruiting
Study of resistance to alkylating chemotherapy in endocrine tumors
This study looks at why some endocrine tumors (tumors in hormone-making glands) stop responding to a specific type of chemotherapy called alkylating agents. Researchers will collect tissue samples to understand how the tumor changes and why the medicine stops working.
UppsalaAges 18 years+ - NCT01174121RecruitingPhase 2
Immunotherapy made from your tumor-fighting immune cells
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for certain metastatic cancers. It’s designed for people whose cancer has not responded to standard treatments and who can safely provide a small tumor sample for cell-making.
Bethesda, MarylandAges 18–72 - NCT04893785RecruitingPhase 2
Cabozantinib plus temozolomide for advanced neuroendocrine lung tumors
This Phase 2 study tests whether combining cabozantinib with temozolomide can control advanced lung or gastrointestinal neuroendocrine tumors that have grown after prior treatments. It also closely monitors safety, including blood counts, organ function, and other side effects.
Naples, CampaniaAges 18 years+ - NCT06091124RecruitingPhase 2
Immunotherapy plus chemo before surgery for neuroendocrine bladder cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT06855095RecruitingPhase 2/Phase 3
PRRT with long-acting hormone therapy for neuroendocrine tumors
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
AmsterdamAges 18 years+ - NCT06424665RecruitingPhase 1
Study of FZ-AD005 for advanced solid tumors
This trial tests a new drug called FZ-AD005 for people with advanced solid tumors, especially small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). It may help if standard treatments are no longer working.
Changsha, HunanAges 18–75 - NCT04074135RecruitingPhase 2
Study of pancreatic tumors in people with VHL
This trial studies the natural course and management of pancreatic neuroendocrine tumors in people with von Hippel–Lindau (VHL) disease. It may help doctors better predict how these pancreatic findings change over time and how to manage them.
Bethesda, MarylandAges 12 years+
Hear when a new Neuroendocrine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine cancer?
- Yes. Clin2 currently lists 123 recruiting neuroendocrine cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.